There is a continuous explosion of new and innovative therapies for men with advanced prostate cancer. Recently, two different PARP-Inhibitors were approved by the FDA for use. Those drugs were the first in their class to have been approved as personalized therapy for certain individuals with advanced prostate cancer. Today, we have Dr. Emmanuel Antonarakis, a world-class expert in the area of targeted therapy for prostate cancer, joining us to talk about the two new medications and explain who might be eligible for that kind of therapy. Be sure to stay tuned for more! Dr. Antonarakis is a Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, as well as being Director of Prostate Cancer Medical Oncology Research and Co-Director of the Prostate Cancer Multidisciplinary Clinic, also at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Since 2010, he has been on the Johns Hopkins faculty as an attending physician and translational researcher in the oncology department. Dr. Antonarakis' clinical interests include the management of prostate cancer. His research focus has included the development of novel androgen-directed therapies, genetically-targeted therapies, immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision on oncology approaches. He is the author of over 290 peer-reviewed research articles and several book chapters. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show highlights: Dr. Antonarakis explains what led him down his chosen path. Dr. Antonarakis explains what a PARP-inhibitor is. Dr. Antonarakis talks about the PARP-inhibitors that are currently available for individuals with prostate cancer. These targeted therapies are not the same as chemotherapy. Dr. Antonarakis explains which men with prostate cancer could be candidates for a PARP-inhibitor. The type of genetic testing needed to determine who could be eligible for treatment with a PARP-inhibitor. Dr. Antonarakis talks about the points along the cancer journey when he would recommend genetic testing. The benefits, risks, and side effects of PARP-inhibitors. Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link here, on our podcast website) Join our Facebook group Follow Dr. Pohlman on Twitter and Instagram Go to the Prostate Health Academy to sign up for the wait-list for our bonus video content. You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related